Your browser doesn't support javascript.
loading
Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? - Authors' reply.
Bowman, Simon J; Dorner, Thomas; Mariette, Xavier; Luo, Wen-Lin; Hueber, Wolfgang.
Afiliação
  • Bowman SJ; Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK; Institute of Inflammation and Ageing, College of Medical and Dental Sciences and National Institute for Health Research Birmingham Biomedical Research Centre, University of Birmingham, Birmingham,
  • Dorner T; Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany.
  • Mariette X; Université Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, INSERM U1184, Le Kremlin Bicêtre, France.
  • Luo WL; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Hueber W; Novartis Pharma, Basel, Switzerland.
Lancet ; 400(10355): 808-809, 2022 09 10.
Article em En | MEDLINE | ID: mdl-36088946
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Sjogren Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Sjogren Idioma: En Ano de publicação: 2022 Tipo de documento: Article